



Redsense Medical initiates sales activities in Australia following TGA approval of Redsense Clamp

Halmstad, Sweden, November 7, 2025 – Redsense Medical AB (publ) (“Redsense” or “the Company”) announces that the Redsense Clamp System has been granted regulatory approval from the Australian Therapeutic Goods Administration (TGA), allowing the product to be sold and marketed in Australia. With the registration now in place, Redsense and its local distribution partner, Regional Health Care Group (RHCG), are initiating preparations for sales, training, and education activities in the market.

RHCG was appointed as Redsense’s distributor for Australia in anticipation of the Clamp, and has been awaiting approval before starting commercial activities. With the Redsense Clamp now registered by the TGA, the companies can begin coordinated preparations to introduce the system to dialysis clinics across the country.

“This registration allows us to take the first concrete step toward establishing Redsense in Australia and we can now begin working closely with our partner RHCG to prepare for market introduction and support improved patient safety in dialysis care.” says Sebastien Bollue, CEO of Redsense Medical AB.

RHCG is an established distributor of medical technology across Australia and New Zealand and was acquired by Henry Schein, Inc. in 2023. Henry Schein is also one of Redsense’s key distribution partners in the United States, and the connection strengthens the collaboration framework for Redsense’s expansion into new markets.

Contact information

For more information, please contact:
Sebastien Bollue, CEO
Telephone: +46 72-171 1264
E-mail: [sebastien.bollue \(at\) redsensemical.com](mailto:sebastien.bollue@redsensemical.com)

Redsense Medical AB (publ), 556646-4862

About Redsense Medical

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The Redsense Medical share is listed on Spotlight Stock Market (REDS)